CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome

Koumpis, Epameinondas; Tassi, Iliana; Malea, Theodora; Papathanasiou, Konstantina; Papakonstantinou, Ioannis; Serpanou, Anastasia; Tsolas, Evangelos; Kapsali, Eleni; Vassilakopoulos, Theodoros P.; Papoudou‐Bai, Alexandra; Hatzimichael, Eleftheria

doi:10.1016/j.prp.2021.153567

Cited by 14 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with these findings, heparanase-induced shedding of CD138 (Syndecan-1), expressed on normal and malignant plasma cells, promotes myeloma cell migration and invasion by coupling VLA-4 to the vascular endothelial cell growth factor receptor-2 (VEGFR2) (33). Loss of CD56 or downregulation of CD44, two molecules involved in the adhesion of myeloma cells to BMSCs and endothelial cells, are frequently observed in advanced and disseminated disease states (34)(35)(36)(37)(38). Platelets, produced by megakaryocytes in the BM, have been found to protect disseminated cancer cells from immune attack and shear stress in the blood stream (39,40).…”

Section: Cellular Compartments Of the Tme Bone Marrow Stromal And Vas...mentioning

confidence: 73%

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease

Förster

Radpour

2022

Front. Oncol.

View full text Add to dashboard Cite

Multiple myeloma (MM) is the most common malignant monoclonal disease of plasma cells. Aside from classical chemotherapy and glucocorticoids, proteasome inhibitors, immunomodulatory agents and monoclonal antibodies are used in the current treatment scheme of MM. The tumor microenvironment (TME) plays a fundamental role in the development and progression of numerous solid and non-solid cancer entities. In MM, the survival and expansion of malignant plasma cell clones heavily depends on various direct and indirect signaling pathways provided by the surrounding bone marrow (BM) niche. In a number of MM patients, single plasma cell clones lose their BM dependency and are capable to engraft at distant body sites or organs. The resulting condition is defined as an extramedullary myeloma (EMM). EMMs are highly aggressive disease stages linked to a dismal prognosis. Emerging literature demonstrates that the dynamic interactions between the TME and malignant plasma cells affect myeloma dissemination. In this review, we aim to summarize how the cellular and non-cellular BM compartments can promote plasma cells to exit their BM niche and metastasize to distant intra-or extramedullary locations. In addition, we list selected therapy concepts that directly target the TME with the potential to prevent myeloma spread.

show abstract

Section: Cellular Compartments Of the Tme Bone Marrow Stromal And Vas...mentioning

confidence: 73%

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease

Förster

Radpour

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…CD56 is a membrane glycoprotein expressed on MM cells but not on normal PCs. A lack of CD56 at diagnosis was found to be correlated with poorer prognosis [ 15 , 16 , 19 ]. However, other studies have not only failed to replicate these findings but also reported contradictory results [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…At diagnosis, a few specific surface antigens measured by MFC can identify the pathogenic clone and further stratify it. Some markers, such as CD19, CD117, CD45, and CD56, were found to have prognostic significance [ 14 , 15 , 16 , 17 , 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival

Even‐Zohar

Pick

Hofstetter

et al. 2022

JCM

View full text Add to dashboard Cite

Surface antigens are commonly used in flow cytometry assays for the diagnosis of multiple myeloma (MM). Some of these are directly involved in MM pathogenesis or interactions with the microenvironment, but most are used for either diagnostic or prognostic purposes. In a previous study, we showed that in-vitro, CD24-positive plasma cells exhibit a less tumorigenic phenotype. Here, we assessed the prognostic importance of CD24 expression in patients newly diagnosed with MM as it correlates to their clinical course. Immunophenotyping by flow cytometry of 124 patients uniformly treated by a bortezomib-based protocol was performed. The expression of CD24, CD117, CD19, CD45, and CD56 in bone marrow PCs was tested for correlations to clinical parameters. None of the CD markers correlated with the response rates to first-line therapy. However, patients with elevated CD24+ expression on their PCs at diagnosis had a significantly longer PFS (p = 0.002) and OS (p = 0.044). In contrast, the expression of CD117, CD56, or CD45 was found to have no prognostic value; CD19 expression was inversely correlated with PFS alone (p ˂ 0.001) and not with OS. Thus, elevated CD24 expression on PCs appears to be strongly correlated with survival and can be used as a single-surface antigenic prognostic factor in MM.

show abstract

“…[ 8 ] A recent retrospective study found that CD56 expression did not affect the prognosis of MM, but CD56 deficiency was significantly associated with several adverse prognostic factors (LDH, β2-MG, etc). [ 26 ] In the era of novel therapeutic agents, the prognostic significance of CD56 in MM patients remains controversial. To further investigate the clinical value of CD56, we explored the correlation between CD56 expression and clinicopathological features, cytogenetic features and patient survival.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study

Shang

et al. 2022

Medicine

View full text Add to dashboard Cite

The prognostic value of plasma cell CD56 expression of patients with multiple myeloma (MM) has been reported in many studies, but the results are controversial. This study aimed to examine the prognostic significance of CD56 in MM patients.Eighty seven patients with newly diagnosed MM were enrolled in this study, and their clinical characteristics, immunophenotypes, and cytogenetics were retrospectively analyzed to explore the prognostic significance of CD56 expression. Multiparameter flow cytometry was used to detect MM in bone marrow samples from all patients. Patients were divided into 2 groups based on whether they expressed CD56: CD56 + group and CD56 − group.After 4 cycles of chemotherapy, the overall response rate of the CD56 − patients was lower than that of the CD56 + patients (60.0% vs 81.1%, P = .036). Survival analysis showed that the median progression-free survival (PFS) was 10 months for the CD56 − group and 27 months for the CD56 + group (P = .007). The median overall survival (OS) of patients for the CD56 − group was 25 months versus not reached in the CD56 + group (P = .010). In addition, among the high-risk patients detected by fluorescence in situ hybridization (FISH), the median PFS was 4 months for the CD56 − group and 16 months for the CD56 + group (P = .012). The median OS of the CD56 + group and CD56 − group was 36 months and 15 months, respectively, with statistically significant differences (P = .017).Our study confirmed that CD56 − patients with MM had a worse prognosis than that of CD56 + patients with MM. Among the patients with ≥ 2 high-risk cytogenetics, the existence of the CD56 negativity can further identify MM patients with poor PFS and OS.

show abstract

CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome

Cited by 14 publications

References 29 publications

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival

Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study

Contact Info

Product

Resources

About